PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
No Thumbnail Available
Identifiers
Date
2021-07-03
Authors
Tabernero, J.
Bekaii-Saab, T.
Aguilera, M. Safont
Cubillo, A.
Garcia-Carbonero, R.
Limon, L.
Rodriguez-Salas, N.
Tournigand, C.
Borg, C.
Raghav, K.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
